Semaglutide (Ozempic/Wegovy) for Weight Loss: Mechanisms, Clinical Evidence, and UK Prescribing

Semaglutide — marketed as Ozempic (1mg, licensed for type 2 diabetes) and Wegovy (2.4mg, licensed specifically for weight management) — is currently the most evidence-supported pharmacological treatment for obesity. Its effect size substantially exceeds prior weight loss medications, and the STEP trial programme provides high-quality RCT data from large populations.

Mechanism of Action

Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist — a synthetic analogue of the naturally occurring incretin hormone GLP-1. It activates GLP-1 receptors throughout the body.

Weight-relevant effects:

Central Appetite Suppression

GLP-1 receptors are expressed in the hypothalamus, brainstem, and limbic system — regions controlling appetite, satiety, and food reward. Semaglutide:

Reduces appetite and food cravings by activating hypothalamic satiety centres
Reduces hedonic eating — the reward-driven eating that occurs independently of caloric need
Lowers the reward value of food in the nucleus accumbens, reducing calorie-seeking behaviour

Evidence: A 2021 Cell Metabolism study (O'Neil et al.) using fMRI found semaglutide reduced brain activation in reward centres in response to food images — directly demonstrating appetite suppression at the neurological level.

Gastric Emptying Delay

Semaglutide slows gastric emptying — food moves from the stomach to the small intestine more slowly. This:

Reduces postprandial glucose peaks (relevant for diabetes)
Extends the feeling of fullness after eating
Reduces meal size at the neurological satiety signal threshold

Pancreatic Effects

Semaglutide stimulates glucose-dependent insulin release and suppresses glucagon — relevant primarily for glycaemic control in type 2 diabetes rather than for weight loss directly.

Clinical Evidence: The STEP Trials

The STEP (Semaglutide Treatment Effect in People with Obesity) trial programme is the most comprehensive RCT evidence base for any weight loss medication.

STEP 1 (NEJM, 2021, n=1,961)

Weekly subcutaneous semaglutide 2.4mg vs. placebo for 68 weeks in adults with BMI ≥30 (or ≥27 with ≥1 comorbidity) without diabetes:

Mean weight loss: −14.9% with semaglutide vs −2.4% with placebo
≥5% weight loss: 86% of semaglutide group vs. 32% of placebo
≥10% weight loss: 69% vs. 12%
≥15% weight loss: 50% vs. 5%
≥20% weight loss: 33% vs. 2%

This represents weight loss approximately 3× greater than any previously approved weight loss pharmacotherapy.

STEP 2 (Lancet, 2021, n=1,210)

Semaglutide 2.4mg in adults with type 2 diabetes and BMI ≥27:

Mean weight loss: −9.6% vs. −3.4% placebo
Significant HbA1c reduction alongside weight loss

STEP 3 (JAMA, 2021, n=611)

Semaglutide 2.4mg combined with intensive behavioural intervention:

Mean weight loss: −16.0% vs. −5.7%
Combination produced greater weight loss than medication alone

STEP 4 (Maintenance, JAMA, 2021)

After 20 weeks on semaglutide, participants randomised to continue or switch to placebo:

Continued semaglutide: additional −7.9% weight loss
Switched to placebo: +6.9% weight regain
Demonstrating that weight loss is sustained only during active treatment — weight returns when medication is discontinued

Key implication: Semaglutide treats obesity as a chronic condition requiring ongoing treatment. It is not a course of treatment that "cures" obesity; discontinuation results in substantial weight regain in most patients.

UK Prescribing Context

Ozempic (Semaglutide 1mg) — Licensed for Type 2 Diabetes

Ozempic is MHRA-licensed for type 2 diabetes management. Weight loss is a beneficial secondary effect but not the licensed indication.

NICE Technology Appraisal TA924 (2023) recommends semaglutide (Ozempic) for type 2 diabetes in patients not adequately controlled on existing medications.

Wegovy (Semaglutide 2.4mg) — Licensed for Weight Management

Wegovy is MHRA-licensed for chronic weight management in adults with:

BMI ≥30 kg/m², or
BMI ≥27 kg/m² with ≥1 weight-related comorbidity (hypertension, type 2 diabetes, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease)

NICE Technology Appraisal TA875 (2023): NICE recommends Wegovy through specialist weight management services (Tier 3) for:

BMI ≥35 with ≥1 weight-related comorbidity
Or BMI ≥30 with high cardiovascular risk (SCORE2 ≥10%)
In adults who have not responded adequately to behavioural interventions alone

NHS rollout: NICE approved Wegovy for NHS use in 2023 but noted availability through NHS specialist services would be phased due to supply constraints.

Private prescription: Wegovy and compounded semaglutide preparations are available through private prescribers. Patients should ensure prescribers are GMC-registered and follow MHRA guidance — unregulated compounded semaglutide products (not approved by MHRA) carry safety risks.

Side Effects

The most common side effects are gastrointestinal, particularly during dose escalation:

Side Effect	Frequency	Management
Nausea	44% (vs 16% placebo)	Eat smaller meals; avoid fatty/spicy food; typically improves after 4–8 weeks
Diarrhoea	30%	Usually mild; hydration; improves over time
Vomiting	24%	Often linked to nausea; eating smaller meals helps
Constipation	24%	Adequate fluid and fibre intake
Abdominal pain	20%	Usually mild and transient

Rare but serious:

Pancreatitis: Rare association; discontinue if abdominal pain with nausea/vomiting
Thyroid C-cell tumour risk: Signal from rodent studies; contraindicated in patients with personal/family history of medullary thyroid carcinoma or MEN-2
Gallbladder disease: Weight loss itself increases gallstone risk; GLP-1 agonists have an additional modest association

Contraindications

Personal or family history of medullary thyroid carcinoma (MTC)
Multiple Endocrine Neoplasia type 2 (MEN-2)
Pregnancy and breastfeeding (discontinue at least 2 months before planned pregnancy)
Hypersensitivity to semaglutide

Semaglutide and Lifestyle Interventions

STEP 3 data and clinical experience confirm that semaglutide's weight loss effect is largest when combined with behavioural support (dietary counselling, physical activity guidance). The medication reduces appetite and calorie intake; dietary quality during the reduced intake period determines body composition outcomes and long-term health.

Key nutritional consideration: Reduced appetite during semaglutide treatment can result in inadequate protein intake — increasing lean mass loss. Maintaining ≥1.6g/kg protein intake and continuing resistance training is important to preserve muscle mass during semaglutide-induced weight loss.

Disclaimer: This article is for informational and educational purposes only. Semaglutide is a prescription medication that must be prescribed by a registered medical professional following appropriate clinical assessment. Do not use semaglutide products without medical supervision.